Brainstorm Health: FDA Name and Shame, ASCO Abstracts, Non-Opioid Withdrawal Drug


FDA approves first non-opioid drug to help with withdrawal. The Food and Drug Administration (FDA) on Wednesday approved US WorldMeds LLC’s Lucemyra, the first-ever non-opioid drug meant to treat opioid withdrawal symptoms in the U.S. The drug is only approved for adults for two weeks’ worth of therapy; as the opioid addiction crisis rages on, public health officials have been calling for more experimentation with non-opioid pain—and withdrawal—medicines. (Reuters)

ASCO fever begins. The American Society of Clinical Oncology’s (ASCO) annual meeting, the largest cancer conference in the world, is around the corner—and companies are beginning to preview the data they’ll be unveiling at the confab. Shares of Jounce Therapeutics plunged 32% Thursday as investors recoiled from a lackluster abstract for its new type of cancer therapy, which is also being tested in combination with various cancer immunotherapies. On the other end of the spectrum: Loxo Oncology soared 20% in Thursday trading thanks to strong results for its own experimental therapy LOXO-292, which is being tested in multiple tumor types. (FierceBiotech)

Let’s block ads! (Why?)

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *